Your Technology Probably Isn't Cost-Saving. It Can Still Be Worth Paying For.

Almost every health tech pitch contains a version of the same sentence: our technology lowers the cost of care.

It is the most common economic claim in the sector, and the one least often supported.

The intuition behind it is reasonable. A technology that keeps patients healthier should mean fewer admissions, fewer procedures, less spending. Vaccination and early detection make the logic feel self-evident — spend a little now, avoid a great deal later. Founders lead with the claim in front of investors and payers because it sounds like the strongest possible version of their value proposition.

Health economics draws a line that the pitch deck usually erases. Producing health and reducing spending are separate outcomes. A technology can improve outcomes without being worth its price. A technology can be worth its price without lowering total spending by a single dollar.

Effective, cost-effective, and cost-saving are three different claims. Each carries its own burden of proof. Founders use them interchangeably. Payers never do.

Effective, Cost-Effective, Cost-Saving: Three Claims, Not One

Evaluating a medical technology means separating three questions that are easy to collapse into one.

Effective: does it improve health?

The most basic test. Does the technology actually improve patient health? Does survival improve after treatment? Do symptoms resolve? Is disease prevented? Cost does not enter the question yet. What matters first is whether the clinical effect exists at all.

Cost-Effective: is the health gain worth the spend?

Here the effect is weighed against what it costs to produce. A technology can cost more than the existing standard of care and still be cost-effective, provided the additional health gain justifies the additional spend.

The standard unit for this comparison is the QALY — the quality-adjusted life year. A QALY combines length of life and quality of life into a single measure, which makes health gains from very different interventions comparable to each other. Cost-effectiveness analysis asks how much health you buy with each additional dollar.

Cost-Saving: does total spending actually fall?

The third question is narrower and much harder to satisfy. Does total healthcare spending actually decline after the technology is introduced?

Spend $10,000 on prevention, avoid $20,000 in hospitalizations and surgeries that would otherwise have followed, and total spending falls. That is cost-saving.

The three concepts are connected but not equivalent, and the gap that matters most sits between the second and the third. Cost-effective does not imply cost-saving. A technology that costs more than what it replaces can still be cost-effective if it delivers enough health in return. Cost-saving requires something stricter: total spending, after the technology is in use, has to come down.

Understanding that gap is the starting point for evaluating the economic value of any health technology.

When Prevention Actually Does Save Money

Prevention is often treated as a synonym for cost reduction. Spend on prevention now, avoid treatment costs later. In some cases the structure genuinely holds.

Childhood immunization is the clearest example. According to CDC analysis of childhood immunization, routine vaccination of children born between 1994 and 2023 is estimated to prevent hundreds of millions of illnesses, tens of millions of hospitalizations, and more than a million deaths.

The economics are equally striking. Even after accounting for the cost of the vaccination programs themselves, the analysis finds net benefits in the hundreds of billions of dollars measured against direct medical costs, and in the trillions when societal costs are included. The programs cost money, but the infections, hospitalizations, and complications they avert cost considerably more.

Contraception follows the same structure. The cost of contraception is lower than the cost of the pregnancies, deliveries, and maternal care it prevents, so present spending reduces larger future spending.

Some preventive care really does reach cost-saving. But one qualification matters. Prevention does not reduce spending as a category. When a preventive intervention carries its own cost and patients continue to require other services afterward, total spending does not necessarily fall.

Why the HPV Vaccine Is Cost-Effective but Not Cost-Saving

The HPV vaccine is the standard case for preventive medicine. It prevents cervical cancer and other HPV-related disease, and it produces real health gains. Given the right population, it is a solidly cost-effective preventive strategy.

Prevention does not make it cost-saving. Vaccination carries a direct cost. And because the vaccine does not eliminate HPV-related disease entirely, screening, follow-up diagnostics, and treatment continue to generate spending afterward.

The HPV vaccine produces health, and the health it produces can be worth what it costs. Neither of those facts means total healthcare spending goes down.

The more consequential point is that the same vaccine carries different economics depending on who receives it. Administered to adolescents before HPV exposure, it prevents a large volume of future disease and its cost-effectiveness is high. Administered to adults with a high likelihood of prior exposure, the incremental health gain shrinks. US economic evaluations show a substantial gap between routine adolescent vaccination and expanding eligibility to adults.

What the HPV vaccine demonstrates is the central feature of preventive medicine. Preventing disease and reducing spending are not the same thing, and the economics shift with the target population, the price, and whatever prevention and screening infrastructure already exists.

One Drug, Opposite Verdicts: The Nirsevimab Case

Nirsevimab, the monoclonal antibody used to prevent RSV, makes the point more sharply.

The drug is effective at preventing severe RSV infection during an infant's first RSV season. Economic evaluations in Italy, the Netherlands, Japan, and South Korea have concluded that universal immunization has the potential to be cost-effective. Almost all of them attach the same condition: only if the price per dose falls below a specific threshold. One Dutch study proposed roughly €220 per dose as a justifiable price — and even at that price, the probability of the intervention being cost-effective was 52%.

Push the question further, to whether the drug is cost-saving, and the verdict splits within the drug itself. A Canadian regional analysis shows how. In certain high-risk regions, a strategy targeting high-risk infants was genuinely cost-saving.

In the densely populated southern regions, extending the same drug to universal immunization produced an ICER above $440,000 per QALY — far beyond the range generally accepted as cost-effective, which sits somewhere around $50,000 to $100,000 per QALY. This is not a case of falling short of cost-saving. It crosses into territory that is not cost-effective at all.

Same drug, same country, opposite conclusions. High-risk regions reach cost-saving. Southern regions fail to clear cost-effective.

Nirsevimab reduces healthcare spending only where a high-risk population and a low price happen to coincide. Move slightly off those conditions and the result stops at cost-effective or falls out of the efficient range entirely. It is a precise demonstration of how quickly the intuition that prevention saves money collapses.

A clinically effective drug can be cost-effective or not depending on target population, price, and breadth of application. The subset that reaches cost-saving is narrow.

The implication for health technology companies is direct. Clinical efficacy is the starting line. Explaining economic value requires three additional answers: which patients the product is for, whether it replaces existing care or adds to it, and at what price it will be delivered.

Screening Comes With a Downstream Bill

The pattern is not limited to vaccines. Mammography is the canonical case in early detection. Screening finds cancer sooner and reduces mortality, which is a real health benefit.

Screening does not cost only what the scan costs. An abnormal finding may trigger additional imaging or a biopsy. Some patients receive further testing and treatment for something that turns out not to be cancer. False positives and overdiagnosis carry both cost and harm, and both belong in the accounting.

Evaluating the economics of screening means looking at the entire downstream care pathway a patient enters, not the price of the test.

Studies analyzing the economics of mammography generally find that screening strategies add cost relative to no screening, while producing enough health benefit to justify that cost. That does not make mammography a reducer of total healthcare spending.

Mammography is effective. It can be cost-effective. It is not cost-saving.

Both the HPV vaccine and mammography produce health, and both can be economically worthwhile in the sense that the health is worth its price. Once you account for the cost of using the technology and the spending that follows it, total healthcare costs do not necessarily fall.

What Health Tech Companies Actually Have to Prove

The same medical technology becomes an entirely different story depending on which standard of value you apply to it.

Where the avoided spending exceeds the cost of prevention, as with childhood immunization and contraception, cost-saving is achievable. Where the health gain is clear and the price is justified but downstream spending continues, as with the HPV vaccine and mammography, it is not. RSV prevention lands in either category depending on population and price.

For companies, the consequence is that "it works," "it is cost-effective," and "it reduces healthcare spending" are not interchangeable sentences. Each requires different evidence.

Effective requires demonstrating clinical benefit. Cost-effective requires demonstrating that the cost is reasonable relative to that benefit. Cost-saving requires going further and demonstrating that total healthcare spending actually declines.

What matters is not claiming the strongest version of the three. It is defining precisely which kind of value the technology creates and bringing the evidence that claim requires.

A technology that increases spending while producing greater health value can be a genuinely good medical technology. A technology that also reduces total spending carries a stronger economic claim. Both are defensible positions. Only one of them is the one most companies are actually in.

The same discipline applies to evaluating health technology from the outside. The question is not whether it is good. It is what effect it produces, what that effect costs, and what happens to total spending as a result.

Building good medical technology and proving its economic value are separate problems.

Frequently Asked Questions

What is the difference between cost-effective and cost-saving?

Cost-effective means the health gain justifies the additional spending, even when the technology costs more than what it replaces. Cost-saving means total healthcare spending actually declines after adoption. A technology can be cost-effective without being cost-saving, and most are.

What is a QALY?

A quality-adjusted life year combines length of life and quality of life into a single measure. It allows health gains from very different interventions to be compared on the same scale, which is what makes cost-effectiveness analysis possible across treatment categories.

What ICER is considered cost-effective?

The incremental cost-effectiveness ratio expresses the additional cost required to gain one QALY. Thresholds generally accepted as cost-effective sit somewhere around $50,000 to $100,000 per QALY, though the figure varies by country and payer.

Does preventive care reduce healthcare costs?

Sometimes. Childhood immunization and contraception avert more spending than they cost. Others, including the HPV vaccine and mammography, produce clear health benefits and remain cost-effective while total spending continues to rise, because the intervention carries its own cost and downstream care continues.

About Kakao Ventures

Founded in 2012 and backed by Kakao — Korea's leading tech platform — Kakao Ventures is one of Korea's most active Seed-stage venture capital firms, with approximately $280M USD in AUM. We partner with founders before the path is fully defined, when conviction in people matters more than proof in numbers.

Our portfolio includes Lunit (AI cancer diagnostics), Rebellions (AI semiconductors), and Dunamu (operator of Upbit, one of Asia's largest crypto exchanges).

If you're building at the edge of what's possible — we'd like to hear from you.